Tumor therapy by the preferential activation of a prodrug at tumor cells targeted with an
antibody− enzyme conjugate may allow improved treatment efficacy with reduced side …

The article reviews the background and current status of pretargeting for cancer imaging and
therapy with radionuclides. Pretargeting procedures were introduced∼ 20 years ago as an …

Effective radioimmunotherapy is limited by slow antibody clearance from the circulation,
which results in low tumour to blood ratios and restricts the dose of radiolabelled anti-tumour …

The F (ab ') 2 fragment of the anti-TAG-72 antibody, B72. 3, was covalently linked to
Escherichia coli-derived β-glucuronidase that was modified with methoxypoly (ethylene …

Radiolabeled monoclonal antibodies (mAbs) can target tumors selectively. Sustained
activity levels in nontarget tissues limit their application. Pretargeting approaches using …

Pretargeting methodologies can produce high tumor: blood ratios, but their role in cancer
radioimmunotherapy (RAIT) is uncertain. A pretargeting method was developed using a …

The invention pertains to anti-PSMA antibodies that lack fucosyl residues. The antibodies of
the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity as …

The present invention relates to monoclonal antibodies that bind to the extracellular domain
of prostate-specific membrane antigen (PSMA), hybridoma cell lines producing the …

To test a two-step approach for radioimmunotargeting of renal cell cancer, quadroma cells
secreting antichelate× anti-renal cell carcinoma bispecific antibodies were obtained by …

Long blood half-life is one of the advantages of antibodies over small molecule drugs. At the
same time, prolonged half-life is a problem for imaging applications or in the case of …